Key Points
- Insider sale: Dianthus Therapeutics CAO Edward Carr sold 20,000 shares for approximately $2.03 million at an average price of $101.38, reducing his position by 50%.
- Stock performance and results: DNTH opened at $96.81 after falling 4.3%; the company recently reported a quarterly loss of $0.90 per share, missing estimates, while revenue exceeded expectations.
- Analyst outlook: Analysts maintain a “Moderate Buy” consensus, with an average price target of $129.83, despite one sell rating. Institutional investors own approximately 47.53% of the company.
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) CAO Edward Carr sold 20,000 shares of the company's stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $101.38, for a total value of $2,027,600.00. Following the completion of the sale, the chief accounting officer owned 20,000 shares in the company, valued at $2,027,600. The trade was a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Dianthus Therapeutics Stock Down 4.3%
DNTH stock opened at $96.81 on Friday. Dianthus Therapeutics, Inc. has a twelve month low of $32.22 and a twelve month high of $117.88. The firm has a market cap of $5.29 billion, a PE ratio of -23.33 and a beta of 1.24. The business has a 50 day moving average of $107.03 and a 200 day moving average of $92.84.
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The company had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. On average, research analysts expect that Dianthus Therapeutics, Inc. will post -3.81 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several research firms have recently issued reports on DNTH. Guggenheim reaffirmed a "buy" rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Raymond James Financial restated a "strong-buy" rating and set a $131.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, August 5th. HC Wainwright lifted their target price on shares of Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Dianthus Therapeutics in a report on Friday, July 17th. Finally, Citigroup began coverage on shares of Dianthus Therapeutics in a research note on Friday, September 4th. They issued a "buy" rating and a $156.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $129.83.
View Our Latest Stock Report on DNTH
Institutional Investors Weigh In On Dianthus Therapeutics
Institutional investors have recently modified their holdings of the business. BlackRock Inc. bought a new stake in Dianthus Therapeutics in the 2nd quarter worth about $401,990,000. Wellington Management Group LLP lifted its stake in Dianthus Therapeutics by 24.4% during the 2nd quarter. Wellington Management Group LLP now owns 3,229,882 shares of the company's stock valued at $314,849,000 after acquiring an additional 634,099 shares during the period. ABS Investment Management LLC bought a new position in Dianthus Therapeutics during the 2nd quarter valued at about $194,960,000. Polar Capital Holdings Plc boosted its holdings in shares of Dianthus Therapeutics by 34.3% during the 4th quarter. Polar Capital Holdings Plc now owns 1,004,728 shares of the company's stock valued at $41,405,000 after acquiring an additional 256,725 shares during the last quarter. Finally, Jennison Associates LLC purchased a new stake in shares of Dianthus Therapeutics during the 1st quarter valued at about $40,713,000. 47.53% of the stock is owned by hedge funds and other institutional investors.
Dianthus Therapeutics Company Profile
(
Get Free Report)
Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for complement-mediated diseases. The complement system is part of the immune system, and abnormal activation can contribute to autoimmune and inflammatory disorders. Dianthus is developing therapies designed to selectively inhibit complement activity while offering potentially durable treatment effects.
The company's lead product candidate, DNTH103, is an investigational monoclonal antibody designed to inhibit C1s, a protein involved in the classical complement pathway.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
